Thymulin modulates cytokine release by peripheral blood mononuclear cells: a comparison between healthy volunteers and patients with systemic lupus erythematosus.

Safieh-Garabedian B, Ahmed K, Khamashta MA, Taub NA, Hughes GR

International archives of allergy and immunology1 Jan 1993Cited by 26 (Europe PMC)

PMID8508050DOI10.1159/000236509PepBankPUB-08508050

Publisher page PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study8

8 results from studies that gave the peptide. No result from this study comes from people.

01LabIn vitro (cells)Mechanism
In stimulated PBMC from healthy volunteers, thymulin increased IL-1 alpha release significantly.
In plain wordsIn cells from healthy volunteers, thymulin increased IL-1 alpha release.
Peptide
Thymulin (serum thymic factor)
Outcome
IncreaseIL-1 alpha release in healthy volunteers
Study
humann: not reported in source
Stimulated peripheral blood mononuclear cells from healthy volunteers
Outcome group
Inflammation markers · Immune and inflammation
Studied dose
1 ng/ml · 24 hAs given in this study (human).
Source sentences
Summary
Thymulin (1 ng/ml) resulted in a significant (p < 0.01) increase in IL-1 alpha in the volunteers
1 context sentence(design, population, supporting numbers)
Summary · context
In this study, thymulin was tested in vitro for its effect on the release of IL-1 alpha, IL-2, IL-6 and TNF alpha from peripheral blood mononuclear cells (PBMC) obtained from normal volunteers and patients with active systemic lupus erythematosus (SLE).
Report a problemFND-0850805001
02LabIn vitro (cells)Mechanism
In stimulated PBMC from active SLE patients, thymulin inhibited IL-1 alpha at all tested doses.
In plain wordsIn cells from lupus patients, thymulin reduced IL-1 alpha release at all tested doses.
Peptide
Thymulin (serum thymic factor)
Outcome
DecreaseIL-1 alpha release in SLE
Study
humann: not reported in source
Stimulated peripheral blood mononuclear cells from patients with active systemic lupus erythematosus
Outcome group
Inflammation markers · Immune and inflammation
Studied dose
all dose levels tested · 24 hAs given in this study (human).
Source sentences
Summary
Thymulin (1 ng/ml) resulted in a significant (p < 0.01) increase in IL-1 alpha in the volunteers and a significant (p < 0.05) inhibition of this cytokine at all dose levels tested in SLE patients, whose basal levels of IL-1 alpha were significantly (p < 0.05) higher.
1 context sentence(design, population, supporting numbers)
Summary · context
In this study, thymulin was tested in vitro for its effect on the release of IL-1 alpha, IL-2, IL-6 and TNF alpha from peripheral blood mononuclear cells (PBMC) obtained from normal volunteers and patients with active systemic lupus erythematosus (SLE).
Report a problemFND-0850805002
03LabIn vitro (cells)Mechanism
In stimulated PBMC from SLE patients, thymulin inhibited IL-2 release significantly at 1,000 ng/ml.
In plain wordsIn cells from lupus patients, thymulin reduced IL-2 release.
Peptide
Thymulin (serum thymic factor)
Outcome
DecreaseIL-2 release in SLE
Study
humann: not reported in source
Stimulated peripheral blood mononuclear cells from patients with active systemic lupus erythematosus
Outcome group
Inflammation markers · Immune and inflammation
Studied dose
1,000 ng/ml · 24 hAs given in this study (human).
Source sentences
Summary
Thymulin significantly (p < 0.05) inhibited IL-2 only in SLE patients at 1,000 ng/ml.
1 context sentence(design, population, supporting numbers)
Summary · context
In this study, thymulin was tested in vitro for its effect on the release of IL-1 alpha, IL-2, IL-6 and TNF alpha from peripheral blood mononuclear cells (PBMC) obtained from normal volunteers and patients with active systemic lupus erythematosus (SLE).
Report a problemFND-0850805003
04LabIn vitro (cells)Mechanism
In stimulated PBMC from healthy volunteers, thymulin inhibited IL-6 release at all tested doses.
In plain wordsIn cells from healthy volunteers, thymulin reduced IL-6 release at all tested doses.
Peptide
Thymulin (serum thymic factor)
Outcome
DecreaseIL-6 release in healthy volunteers
Study
humann: not reported in source
Stimulated peripheral blood mononuclear cells from healthy volunteers
Outcome group
Inflammation markers · Immune and inflammation
Studied dose
all dose levels tested · 24 hAs given in this study (human).
Source sentences
Summary
At all dose levels tested, thymulin significantly (p < 0.01) inhibited IL-6 in volunteers, and, only at 1,000 ng/ml, it significantly (p < 0.05) inhibited it in patients with SLE.
1 context sentence(design, population, supporting numbers)
Summary · context
In this study, thymulin was tested in vitro for its effect on the release of IL-1 alpha, IL-2, IL-6 and TNF alpha from peripheral blood mononuclear cells (PBMC) obtained from normal volunteers and patients with active systemic lupus erythematosus (SLE).
Report a problemFND-0850805004
05LabIn vitro (cells)Mechanism
In stimulated PBMC from SLE patients, thymulin inhibited IL-6 release significantly only at 1,000 ng/ml.
In plain wordsIn cells from lupus patients, thymulin reduced IL-6 release only at the highest reported dose.
Peptide
Thymulin (serum thymic factor)
Outcome
DecreaseIL-6 release in SLE
Study
humann: not reported in source
Stimulated peripheral blood mononuclear cells from patients with active systemic lupus erythematosus
Outcome group
Inflammation markers · Immune and inflammation
Studied dose
1,000 ng/ml · 24 hAs given in this study (human).
Source sentences
Summary
At all dose levels tested, thymulin significantly (p < 0.01) inhibited IL-6 in volunteers, and, only at 1,000 ng/ml, it significantly (p < 0.05) inhibited it in patients with SLE.
1 context sentence(design, population, supporting numbers)
Summary · context
In this study, thymulin was tested in vitro for its effect on the release of IL-1 alpha, IL-2, IL-6 and TNF alpha from peripheral blood mononuclear cells (PBMC) obtained from normal volunteers and patients with active systemic lupus erythematosus (SLE).
Report a problemFND-0850805005
06LabIn vitro (cells)Mechanism
In stimulated PBMC from healthy volunteers, thymulin inhibited TNF alpha release significantly at 1,000 ng/ml.
In plain wordsIn cells from healthy volunteers, thymulin reduced TNF alpha release.
Peptide
Thymulin (serum thymic factor)
Outcome
DecreaseTNF alpha release in healthy volunteers
Study
humann: not reported in source
Stimulated peripheral blood mononuclear cells from healthy volunteers
Outcome group
Inflammation markers · Immune and inflammation
Studied dose
1,000 ng/ml · 24 hAs given in this study (human).
Source sentences
Summary
At the 1,000 ng/ml dose level, TNF alpha was significantly (p < 0.05) inhibited in both volunteers and SLE patients, whose basal levels of this cytokine were significantly (p < 0.05) higher.(ABSTRACT TRUNCATED AT 250 WORDS)
1 context sentence(design, population, supporting numbers)
Summary · context
In this study, thymulin was tested in vitro for its effect on the release of IL-1 alpha, IL-2, IL-6 and TNF alpha from peripheral blood mononuclear cells (PBMC) obtained from normal volunteers and patients with active systemic lupus erythematosus (SLE).
Report a problemFND-0850805006
07LabIn vitro (cells)Mechanism
In stimulated PBMC from SLE patients, thymulin inhibited TNF alpha release significantly at 1,000 ng/ml.
In plain wordsIn cells from lupus patients, thymulin reduced TNF alpha release.
Peptide
Thymulin (serum thymic factor)
Outcome
DecreaseTNF alpha release in SLE
Study
humann: not reported in source
Stimulated peripheral blood mononuclear cells from patients with active systemic lupus erythematosus
Outcome group
Inflammation markers · Immune and inflammation
Studied dose
1,000 ng/ml · 24 hAs given in this study (human).
Source sentences
Summary
At the 1,000 ng/ml dose level, TNF alpha was significantly (p < 0.05) inhibited in both volunteers and SLE patients, whose basal levels of this cytokine were significantly (p < 0.05) higher.(ABSTRACT TRUNCATED AT 250 WORDS)
1 context sentence(design, population, supporting numbers)
Summary · context
In this study, thymulin was tested in vitro for its effect on the release of IL-1 alpha, IL-2, IL-6 and TNF alpha from peripheral blood mononuclear cells (PBMC) obtained from normal volunteers and patients with active systemic lupus erythematosus (SLE).
Report a problemFND-0850805007
08LabIn vitro (cells)Mechanism
In PBMC from healthy volunteers, thymulin did not significantly inhibit IL-2 release.
In plain wordsIn cells from healthy volunteers, thymulin did not significantly reduce IL-2 release.
Peptide
Thymulin (serum thymic factor)
Outcome
No significant changeIL-2 release in healthy volunteers
Study
humann: not reported in source
Stimulated PBMC from healthy volunteers
Outcome group
Inflammation markers · Immune and inflammation
Studied dose
Dose not stated · 24 hAs given in this study (human).
Source sentences
Summary
Thymulin significantly (p < 0.05) inhibited IL-2 only in SLE patients at 1,000 ng/ml.
1 context sentence(design, population, supporting numbers)
Summary · context
In this study, thymulin was tested in vitro for its effect on the release of IL-1 alpha, IL-2, IL-6 and TNF alpha from peripheral blood mononuclear cells (PBMC) obtained from normal volunteers and patients with active systemic lupus erythematosus (SLE).
Report a problemFND-0850805008

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 3Current
21 Oct 2026, 15:58 UTC
Study results updated
Version 2
21 Oct 2026, 13:55 UTC
Study data updated · source update from Europe PMC
Version 1
21 Oct 2026, 12:50 UTC
First added · source update from Europe PMC

Thymulin modulates cytokine release by peripheral blood mononuclear cells: a comparison between healthy volunteers and patients with systemic lupus erythematosus.

Summary

Results from this study8

Version history

Subjects

Publication types

MeSH terms